AU2009268372B2 - Method of treating blepharitis - Google Patents

Method of treating blepharitis Download PDF

Info

Publication number
AU2009268372B2
AU2009268372B2 AU2009268372A AU2009268372A AU2009268372B2 AU 2009268372 B2 AU2009268372 B2 AU 2009268372B2 AU 2009268372 A AU2009268372 A AU 2009268372A AU 2009268372 A AU2009268372 A AU 2009268372A AU 2009268372 B2 AU2009268372 B2 AU 2009268372B2
Authority
AU
Australia
Prior art keywords
subject
azithromycin
blepharitis
eye
infectious
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009268372A
Other languages
English (en)
Other versions
AU2009268372A1 (en
Inventor
Joseph B. Boyd
Jose L. Boyer
Romulus Kimbro Brazzell
Kurt E. Brubaker
Reza Haque
John C. Ice
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inspire Pharmaceuticals Inc
Original Assignee
Inspire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inspire Pharmaceuticals Inc filed Critical Inspire Pharmaceuticals Inc
Publication of AU2009268372A1 publication Critical patent/AU2009268372A1/en
Application granted granted Critical
Publication of AU2009268372B2 publication Critical patent/AU2009268372B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AU2009268372A 2008-07-10 2009-07-10 Method of treating blepharitis Ceased AU2009268372B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7977208P 2008-07-10 2008-07-10
US61/079,772 2008-07-10
PCT/US2009/050311 WO2010006306A1 (en) 2008-07-10 2009-07-10 Method of treating blepharitis

Publications (2)

Publication Number Publication Date
AU2009268372A1 AU2009268372A1 (en) 2010-01-14
AU2009268372B2 true AU2009268372B2 (en) 2015-06-04

Family

ID=41507457

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009268372A Ceased AU2009268372B2 (en) 2008-07-10 2009-07-10 Method of treating blepharitis

Country Status (7)

Country Link
US (1) US8349806B2 (https=)
EP (1) EP2313103B1 (https=)
JP (2) JP2011527709A (https=)
AU (1) AU2009268372B2 (https=)
CA (1) CA2730120A1 (https=)
MX (1) MX2011000247A (https=)
WO (1) WO2010006306A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001292683A1 (en) 2000-09-15 2002-03-26 Bruder Healthcare Company Wound and therapy compress and dressing
US9925087B2 (en) 2000-09-15 2018-03-27 Bruder Healthcare Company, Llc Wound and therapy compress and dressing
US10105259B2 (en) 2000-09-15 2018-10-23 Bruder Healthcare Company, Llc Wound and therapy compress and dressing
JP2011527709A (ja) 2008-07-10 2011-11-04 インスパイアー ファーマシューティカルズ，インコーポレイティド 眼瞼炎の治療方法
EP2393355A4 (en) * 2009-01-23 2012-07-25 Inspire Pharmaceuticals Inc METHOD FOR TREATING A DRY EYE WITH AZITHROMYCIN
WO2012092378A1 (en) * 2010-12-29 2012-07-05 Inspire Pharmaceuticals, Inc. Method for treating blepharitis
US20130281390A1 (en) * 2010-12-29 2013-10-24 Kurt E. Brubaker Method for treating dry eye
CA2840626A1 (en) * 2011-06-29 2013-01-03 Insite Vision Incorporated Methods of treating recurrent meibomian glands disorder and thereby decreasing the frequency of recurrence
WO2013191167A1 (ja) * 2012-06-19 2013-12-27 参天製薬株式会社 ヘアレス動物の眼瞼状態の変化方法
WO2014143139A1 (en) 2013-03-15 2014-09-18 Bruder Healthcare Company Wound and therapy compress and dressing
CN104045674B (zh) * 2014-05-21 2017-01-04 丽珠医药集团股份有限公司 一种阿奇霉素的制备方法
CN105106109A (zh) * 2015-09-11 2015-12-02 江苏锦宇环境工程有限公司 一种阿奇霉素缓释滴眼剂的制备方法
KR20180081597A (ko) * 2015-12-22 2018-07-16 니치유 가부시키가이샤 누액 유층 안정화제 및 이것을 함유하는 점안제
US12011388B2 (en) 2016-03-01 2024-06-18 The Hilsinger Company Parent, Llc Therapeutic thermal compress with phase-change material
US12156831B2 (en) 2016-03-01 2024-12-03 The Hilsinger Company Parent, Llc Therapeutic eye compress system
US12029681B2 (en) 2016-03-01 2024-07-09 The Hilsinger Company Parent, Llc Therapeutic eye mask system
US9981041B2 (en) * 2016-08-23 2018-05-29 Ira Jason Salzman Ophthalmic lubricating spray
USD871598S1 (en) 2016-11-30 2019-12-31 Bruder Healthcare Company, Llc Therapeutic eye mask
USD844795S1 (en) 2016-11-30 2019-04-02 Bruder Healthcare Company, Llc Therapeutic eye mask
CN109381707B (zh) * 2017-08-03 2022-02-15 沈阳药科大学 一种阿奇霉素离子对脂质体滴眼液及其制备方法
JP2023133646A (ja) * 2020-06-26 2023-09-27 参天製薬株式会社 脂質分泌促進剤
US20220160668A1 (en) * 2020-11-23 2022-05-26 Sight Sciences, Inc. Formulations and methods for treating conditions of the eye
US20240050446A1 (en) * 2021-02-25 2024-02-15 Sun Pharmaceutical Industries Limited Dexamethasone for treatment of blepharitis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1075837A2 (en) * 1999-08-09 2001-02-14 S.I.F.I. Società Industria Farmaceutica Italiana S.p.A. Process for the preparation of aqueous formulations for ophthalmic use
US20040266702A1 (en) * 1999-03-31 2004-12-30 Insite Vision Incorporated Topical treatment or prevention of ocular infections

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861411B1 (en) * 1997-12-02 2005-03-01 Pfizer, Inc. Method of treating eye infections with azithromycin
US6455583B1 (en) * 1998-05-08 2002-09-24 The University Of Miami Method for treating meibomian gland disease
US7056893B2 (en) * 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
US7063857B1 (en) * 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
PE20020578A1 (es) * 2000-10-10 2002-08-14 Upjohn Co Una composicion de antibiotico topico para el tratamiento de infecciones oculares
HRP20010301A2 (en) * 2001-04-27 2001-12-31 Pliva D D New therapeutic indication for azithromycin in the treatment of non-infective inflammatory diseases
US7332470B2 (en) * 2003-04-15 2008-02-19 The Regents Of The University Of California Methods and compositions for treating ocular disease
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US20050137205A1 (en) * 2003-12-22 2005-06-23 Van Breen Eduard T. Formulation for treating periocular disease
WO2005110374A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
US8425929B2 (en) * 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US8372814B2 (en) * 2004-06-07 2013-02-12 Ista Pharmaceuticals, Inc. Ophthalmic formulations and uses thereof
US8349352B2 (en) * 2005-02-04 2013-01-08 Auburn University Therapeutic contact lenses with anti-fungal delivery
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
US7247623B2 (en) * 2005-08-19 2007-07-24 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with non-drying antihistamines
JP2009514969A (ja) * 2005-11-09 2009-04-09 コンビナトアールエックス インコーポレーティッド 医学的状態を治療するための方法、組成物、およびキット
EP1945227A4 (en) * 2005-11-09 2009-09-30 Dow Pharmaceutical Sciences AZITHROMYCIN FOR THE TREATMENT OF GRANULOMATOUS ROSACEA
KR20140093764A (ko) * 2006-02-09 2014-07-28 산텐 세이야꾸 가부시키가이샤 안정한 제제와 그 제조 및 사용 방법
BRPI0714815A2 (pt) * 2006-08-07 2013-05-21 Bausch & Lomb composiÇço, e, uso de um (a) agonista e (b) um agente anti-infeccioso
US11078262B2 (en) * 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
US20080286338A1 (en) * 2007-05-15 2008-11-20 Boston Foundation For Sight Drug delivery system with scleral lens
JP2011527709A (ja) 2008-07-10 2011-11-04 インスパイアー ファーマシューティカルズ，インコーポレイティド 眼瞼炎の治療方法
EP2393355A4 (en) 2009-01-23 2012-07-25 Inspire Pharmaceuticals Inc METHOD FOR TREATING A DRY EYE WITH AZITHROMYCIN

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040266702A1 (en) * 1999-03-31 2004-12-30 Insite Vision Incorporated Topical treatment or prevention of ocular infections
EP1075837A2 (en) * 1999-08-09 2001-02-14 S.I.F.I. Società Industria Farmaceutica Italiana S.p.A. Process for the preparation of aqueous formulations for ophthalmic use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Donnenfeld et al (2008) Continuing Medical Education Supplement to Refractive Eyecare. Volume 12(4) Pages 1-16 *
John, T & Shah, AA (2008) Ann Ophthalmol. Volume 40. Pages 68-74 *
Solomon, KD. RX Perspective New Drop Aimed at Lid Margin Disease. Ophthalmology Management. 1 April 2008. [retrieved from Internet 16 August 2013] URL: http://www.ophthalmologymanagement.com/printarticle.aspx?articleID=101362 *

Also Published As

Publication number Publication date
JP2011527709A (ja) 2011-11-04
EP2313103B1 (en) 2014-06-18
US20100022465A1 (en) 2010-01-28
EP2313103A4 (en) 2012-08-08
AU2009268372A1 (en) 2010-01-14
WO2010006306A1 (en) 2010-01-14
CA2730120A1 (en) 2010-01-14
MX2011000247A (es) 2011-03-30
US8349806B2 (en) 2013-01-08
EP2313103A1 (en) 2011-04-27
JP2014240433A (ja) 2014-12-25

Similar Documents

Publication Publication Date Title
AU2009268372B2 (en) Method of treating blepharitis
Luchs Efficacy of topical azithromycin ophthalmic solution 1% in the treatment of posterior blepharitis
Harbour et al. Pars plana vitrectomy for chronic pseudophakic cystoid macular edema
Friedlaender et al. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis
JP7012075B2 (ja) 眼瞼炎の治療に使用するための医薬組成物
Labcharoenwongs et al. A double-masked comparison of 0.1% tacrolimus ointment and 2% cyclosporine eye drops in the treatment of vernal keratoconjunctivitis in children
Miyake et al. ESCRS Binkhorst lecture 2002: pseudophakic preservative maculopathy
Protzko et al. Long-term safety and efficacy of perfluorohexyloctane ophthalmic solution for the treatment of patients with dry eye disease: the KALAHARI study
Asbell et al. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis
US20100190734A1 (en) Method of treating dry eye disease with azithromycin
Zarei-Ghanavati et al. Comparison of the effect of tea tree oil shampoo with regular eyelid shampoo in meibomian gland dysfunction treatment
WO2012092375A1 (en) Method for treating dry eye
EP3072503B1 (en) Ophthalmic composition for the corneal protection
WO2012092378A1 (en) Method for treating blepharitis
CN115518036B (zh) 一种包含左旋咪唑的眼用药物组合物及其制备方法和应用
EP3199163A1 (en) Composition of doxycycline in liposomes for the prevention, improvement and/or treatment of ocular pathologies
Donaldson et al. The effect of moxifloxacin on the normal human cornea
CN113262235B (zh) 新琼寡糖在治疗眼科疾病方面的新用途
US20110245190A1 (en) Method for improving post surgery visual acuity outcome with azithromycin
CN116407496B (zh) 一种包含青蒿素前体药物的滴眼液及其制备方法
Yani et al. Evaluation of clinical efficacy and safety of Bibrocathol 2% eye ointment in the treatment of Chronic Blepharoconjunctivitis
CN118284425A (zh) 丙谷二肽的新用途和包含丙谷二肽的眼用组合物
JP2025519647A (ja) ドライアイ疾患の治療のためのｐｅｄｆ由来短鎖ペプチドを含む組成物
Zhu et al. Clinical analysis of cataract surgery complicated by endophthalmitis
Mannis et al. What is the best treatment approach for severe blepharitis?

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired